Search

Displaying results 2361 - 2370 of 10000 in total
  1. Drug

    Human papillomavirus type 16 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10301
    ApprovedInvestigational

    Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

    Mixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADETSynonyms: L1 protein, Human papillomavirus type 16 Vaccine, Human papillomavirus type 16 L1 capsid protein antigen
  2. Drug

    Human papillomavirus type 18 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10302
    ApprovedInvestigational

    Human papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

    Mixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADETSynonyms: L1 protein, Human papillomavirus type 18 Vaccine, Human papillomavirus type 18 L1 capsid protein antigen
  3. Drug

    RG-7795

    go.drugbank.com/drugs/DB06329
    Investigational

  4. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index
  5. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO … [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance

    Synonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-
  6. Drug

    Polysorbate 20

    go.drugbank.com/drugs/DB11178
    Approved

    Polysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications. … Polysorbate 20 is a polysorbate-type nonionic surfactant used in many commercial, household and pharmaceutical products. It is composed of 20 repeated units of polyethylene glycol via ethoxylation.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide

  8. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. … It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected

  9. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting

  10. Drug

    Mesalazine

    go.drugbank.com/drugs/DB00244
    ApprovedInvestigational

    Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent … the risk of colorectal cancer in conditions like ulcerative colitis is maintained.